ADVB (Advanced Biomed) Ending Cash Position: $2.61 Mil (As of Mar. 2026)


ADVB Advanced Biomed Inc ADVB
12 GF Score
Price $5.35
! 1 Warning Sign
View Full Analysis

What is Advanced Biomed Ending Cash Position?

Advanced Biomed ADVB +5.42% 12 Ending Cash Position is $2.61 Mil as of Mar. 2026. GuruFocus rates ADVB with a GF Score™ of 12/100. The stock has 1 warning sign investors should review.

Advanced Biomed's Ending Cash Position for the quarter that ended in Mar. 2026 was $2.61 Mil.

Advanced Biomed's quarterly Ending Cash Position declined from Sep. 2025 ($2.66 Mil) to Dec. 2025 ($2.61 Mil) but then increased from Dec. 2025 ($2.61 Mil) to Mar. 2026 ($2.61 Mil).

Advanced Biomed's annual Ending Cash Position declined from Jun. 2023 ($2.62 Mil) to Jun. 2024 ($2.61 Mil) but then increased from Jun. 2024 ($2.61 Mil) to Jun. 2025 ($2.90 Mil).

Advanced Biomed Ending Cash Position Related Terms

Advanced Biomed Ending Cash Position Historical Data

* Premium members only.

The historical data trend for Advanced Biomed's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Advanced Biomed Ending Cash Position Chart

Advanced Biomed Annual Data
Trend Jun21 Jun22 Jun23 Jun24 Jun25
Ending Cash Position
0.07 4.78 2.62 2.61 2.90

Advanced Biomed Quarterly Data
Jun21 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Ending Cash Position Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 5.18 2.90 2.66 2.61 2.61
ADVB
12GF Score
Advanced Biomed Inc ADVB
Ending Cash Position is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Advanced Biomed Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

Advanced Biomed's Ending Cash Position for the fiscal year that ended in Jun. 2025 is calculated as

Ending Cash Position= Beginning Cash Position+Net Change in Cash
=2.609+0.295
=2.90

Advanced Biomed's Ending Cash Position for the quarter that ended in Mar. 2026 is calculated as

Ending Cash Position=Beginning Cash Position+Net Change in Cash
=2.611+-0.002
=2.61

Frequently Asked Questions Learn more about Ending Cash Position →
What does a Ending Cash Position of $2.61 Mil mean?
Advanced Biomed (ADVB) has a Ending Cash Position of $2.61 Mil as of Mar. 2026. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on Advanced Biomed and its competitors.
Is Advanced Biomed's Ending Cash Position too high?
Advanced Biomed's current Ending Cash Position is $2.61 Mil. Overall, Advanced Biomed has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Advanced Biomed's Ending Cash Position compare to MBAI and XWEL?
Advanced Biomed's Ending Cash Position of $2.61 Mil can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Ending Cash Position for a Medical Diagnostics & Research company?
A good Ending Cash Position depends on the Medical Diagnostics & Research industry context. However, Ending Cash Position should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Ending Cash Position mean?
A high Ending Cash Position can signal that a stock is expensive relative to its fundamentals. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on Advanced Biomed and its competitors. Advanced Biomed's current Ending Cash Position is $2.61 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Advanced Biomed stock overvalued right now?
Advanced Biomed (ADVB) has a current Ending Cash Position of $2.61 Mil. The current Ending Cash Position is $2.61 Mil. Advanced Biomed's overall GF Score™ is 12/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Ending Cash Position calculated?
Ending Cash Position is calculated from a company's financial statements. For Advanced Biomed (ADVB), the current Ending Cash Position is $2.61 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Advanced Biomed Business Description

Address No. 689-85 Xiaodong Road, Yongkang District, Tainan, TWN
Advanced Biomed Inc operates through its subsidiaries and is mainly engaged in the research and development of various original microfluidic biochip technologies and the provision of tumor precision diagnosis and treatment technology applications. Through the joint application of semiconductor technology and biotechnology, it has developed various technologies and testing equipment for early screening and detection, diagnosis and staging, and treatment of cancer. Its devices: A+Pre, AC-1000, A+CellScan, and A+SCDrop, and three corresponding microfluidic biochips, A+Pre Chip and AC-1000 CTC Enrichment Chip, and A+CellScan Chip, are designed to provide rapid and affordable assay products and services to cancer patients.
12GF Score

Get the complete analysis for ADVB

Ending Cash Position is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$5.35
Price